Cytomx Therapeutics, INC Schedule 13G passive stakes

Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported beneficial ownership of 9.96% of CytomX Therapeutics' common stock as of June 30, 2026.

State Street Corporation has disclosed beneficial ownership of 5.4% of Cytomx Therapeutics' common stock as of June 30, 2026.

Bank of America Corporation has reported a beneficial ownership of 7.0% in CytomX Therapeutics, Inc., holding over 15.1 million shares.

Seven Fleet Master Fund and associated entities have filed a Schedule 13G reporting a 0.5% beneficial ownership stake in CytomX Therapeutics, Inc.

Longitude Capital and its affiliates have reported a 7% beneficial ownership stake in CytomX Therapeutics, Inc.

Venrock Healthcare Capital Partners and affiliates report a 4.6% beneficial ownership stake in CytomX Therapeutics, Inc. as of March 31, 2026.

Kynam Capital Management, LP has filed an amendment reporting a 6.9% beneficial ownership stake in CytomX Therapeutics, Inc.

Point72 Asset Management and Steven A. Cohen have reported a 5% beneficial ownership stake in CytomX Therapeutics, Inc.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting 0% beneficial ownership in CytomX Therapeutics Inc following an internal realignment.

Kynam Capital Management and affiliates report a 5.29% beneficial ownership stake in CytomX Therapeutics, Inc. common stock.

FMR LLC and Abigail P. Johnson report a 14.6% beneficial ownership stake in CytomX Therapeutics Inc. as of December 31, 2025.

A group of Venrock entities and individuals reported a 9.4% beneficial ownership stake in CytomX Therapeutics, Inc. as of September 30, 2025.

Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen have disclosed a 2.5% beneficial ownership stake in CytomX Therapeutics, Inc.

Seven Fleet Master Fund LP and its affiliates reported a 0.02% beneficial ownership stake in CytomX Therapeutics, Inc. as of September 30, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have reported a combined beneficial ownership of 12.4% of CytomX Therapeutics Inc.'s common stock as of October 31, 2025.

FMR LLC and Abigail P. Johnson have disclosed a beneficial ownership of 9.3% of CytomX Therapeutics Inc.'s common stock, totaling 15,396,200 shares.

Perceptive Advisors and related entities have disclosed a 5.9% beneficial ownership stake in CytomX Therapeutics, Inc., holding 9,680,185 shares.

Tang Capital Management and its affiliates report a 7.0% beneficial ownership stake in CytomX Therapeutics, Inc. through a Schedule 13G/A filing.

OrbiMed Advisors LLC has reported a 5.4% beneficial ownership stake in CytomX Therapeutics, Inc. common stock.

Point72 Asset Management, along with its affiliates, has disclosed a 5.1% passive ownership stake in CytomX Therapeutics, Inc., holding over 8 million shares.

FMR LLC and its affiliates, including Abigail P. Johnson, have disclosed a 5.9% beneficial ownership stake in CytomX Therapeutics Inc. common stock.

The Vanguard Group has reported a 5.95% beneficial ownership stake in CytomX Therapeutics Inc., holding 9,379,794 shares of common stock.

A group of investment entities led by Biotechnology Value Fund (BVF) has disclosed a passive beneficial ownership of 3.5% of CytomX Therapeutics, Inc.'s common stock, primarily through exercisable warrants.

Multiple entities associated with Biotechnology Value Fund, including Mark N. Lampert, collectively report beneficial ownership of 6.8% of CytomX Therapeutics, Inc. common stock, primarily through exercisable warrants.

Seven Fleet Partners LP, Seven Fleet Advisors LLC, and Brian Liu have jointly filed a Schedule 13G, reporting a passive beneficial ownership of 0.2% in CytomX Therapeutics, Inc.

Longitude Capital Partners V, LLC and its affiliates have reported a passive beneficial ownership of 7.3% in CytomX Therapeutics, Inc., holding 11,538,461 shares of common stock.

A group of Venrock-affiliated entities and individuals have filed a Schedule 13G, reporting a collective beneficial ownership of 8.2% of CytomX Therapeutics, Inc.'s common stock.

Tang Capital Management, LLC and affiliated entities, including Kevin Tang, have filed an amended Schedule 13G, disclosing a beneficial ownership of 8.4% in CytomX Therapeutics, Inc. as of March 31, 2025.

Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen have jointly disclosed a passive 8.3% beneficial ownership stake in CytomX Therapeutics, Inc., totaling 13,094,400 shares.

Janus Henderson Group plc has filed an amended Schedule 13G indicating it no longer holds any beneficial ownership in CytomX Therapeutics, Inc. as of December 31, 2024.